The effects demonstrated RET inhibition and death of the oncogene-addicted MTC cells but only at serum concentrations that could not be achieved in patients with tolerable doses of imatinib, suggesting weak effectiveness of such combination in MTC [116]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.